IXICO Past Earnings Performance
Past criteria checks 0/6
IXICO has been growing earnings at an average annual rate of 4%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 3.7% per year.
Key information
4.0%
Earnings growth rate
5.9%
EPS growth rate
| Life Sciences Industry Growth | 36.9% |
| Revenue growth rate | 3.7% |
| Return on equity | -10.3% |
| Net Margin | -17.7% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Is IXICO plc (LON:IXI) Potentially Undervalued?
Sep 30
Is It Time To Consider Buying IXICO plc (LON:IXI)?
Apr 13If You Like EPS Growth Then Check Out IXICO (LON:IXI) Before It's Too Late
Feb 25Here's Why I Think IXICO (LON:IXI) Is An Interesting Stock
Nov 20Should You Think About Buying IXICO plc (LON:IXI) Now?
Oct 25Here's Why I Think IXICO (LON:IXI) Is An Interesting Stock
Aug 11Here's Why I Think IXICO (LON:IXI) Is An Interesting Stock
Apr 17IXICO plc (LON:IXI) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Mar 24At UK£1.04, Is It Time To Put IXICO plc (LON:IXI) On Your Watch List?
Mar 22Does IXICO's (LON:IXI) Statutory Profit Adequately Reflect Its Underlying Profit?
Feb 22Did Business Growth Power IXICO's (LON:IXI) Share Price Gain of 146%?
Feb 01
Will Weakness in IXICO plc's (LON:IXI) Stock Prove Temporary Given Strong Fundamentals?
Jan 09I Ran A Stock Scan For Earnings Growth And IXICO (LON:IXI) Passed With Ease
Dec 22Who Has Been Selling IXICO plc (LON:IXI) Shares?
Dec 04What Does IXICO plc's (LON:IXI) Share Price Indicate?
Jul 06Revenue & Expenses BreakdownBeta
How IXICO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 7 | -1 | 4 | 1 |
| 30 Jun 23 | 7 | -1 | 4 | 1 |
| 31 Mar 23 | 8 | 0 | 4 | 1 |
| 31 Dec 22 | 8 | 1 | 4 | 1 |
| 30 Sep 22 | 9 | 1 | 4 | 1 |
| 30 Jun 22 | 8 | 1 | 4 | 1 |
| 31 Mar 22 | 8 | 1 | 4 | 1 |
| 31 Dec 21 | 9 | 1 | 4 | 1 |
| 30 Sep 21 | 9 | 2 | 4 | 1 |
| 30 Jun 21 | 10 | 1 | 4 | 1 |
| 31 Mar 21 | 10 | 1 | 5 | 1 |
| 31 Dec 20 | 10 | 1 | 5 | 1 |
| 30 Sep 20 | 10 | 1 | 5 | 1 |
| 30 Jun 20 | 9 | 1 | 5 | 1 |
| 31 Mar 20 | 9 | 1 | 4 | 1 |
| 31 Dec 19 | 8 | 1 | 4 | 1 |
| 30 Sep 19 | 8 | 0 | 4 | 1 |
| 30 Jun 19 | 7 | 0 | 4 | 1 |
| 31 Mar 19 | 6 | 0 | 4 | 1 |
| 31 Dec 18 | 6 | 0 | 4 | 1 |
| 30 Sep 18 | 5 | -1 | 3 | 1 |
| 30 Jun 18 | 5 | -1 | 3 | 1 |
| 31 Mar 18 | 5 | -1 | 3 | 1 |
| 31 Dec 17 | 4 | -1 | 3 | 1 |
| 30 Sep 17 | 4 | -2 | 3 | 1 |
| 30 Jun 17 | 4 | -2 | 3 | 1 |
| 31 Mar 17 | 4 | -2 | 3 | 2 |
| 31 Dec 16 | 4 | -2 | 3 | 2 |
| 30 Sep 16 | 3 | -2 | 3 | 2 |
| 30 Jun 16 | 3 | -2 | 3 | 1 |
| 31 Mar 16 | 3 | -2 | 3 | 1 |
| 31 Dec 15 | 3 | -1 | 3 | 1 |
| 30 Sep 15 | 3 | -1 | 3 | 1 |
| 31 Mar 15 | 3 | -1 | 3 | 1 |
| 31 Dec 14 | 3 | -1 | 3 | 1 |
| 30 Sep 14 | 3 | -2 | 2 | 1 |
| 31 May 13 | 4 | 1 | 1 | 1 |
Quality Earnings: IXI is currently unprofitable.
Growing Profit Margin: IXI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IXI is unprofitable, but has reduced losses over the past 5 years at a rate of 4% per year.
Accelerating Growth: Unable to compare IXI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IXI is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Return on Equity
High ROE: IXI has a negative Return on Equity (-10.3%), as it is currently unprofitable.